Corcept Therapeutics (CORT) Expected to Announce Earnings on Wednesday

Corcept Therapeutics (NASDAQ:CORT) will likely be announcing its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect Corcept Therapeutics to post earnings of $0.27 per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 5:00 PM ET.

Corcept Therapeutics Stock Down 0.9%

Corcept Therapeutics stock opened at $39.63 on Wednesday. Corcept Therapeutics has a fifty-two week low of $32.99 and a fifty-two week high of $117.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.07 and a current ratio of 3.14. The firm’s 50-day simple moving average is $52.17 and its 200 day simple moving average is $67.68. The stock has a market cap of $4.17 billion, a PE ratio of 45.03 and a beta of 0.25.

Wall Street Analyst Weigh In

CORT has been the topic of several recent research reports. HC Wainwright increased their target price on Corcept Therapeutics from $90.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Truist Financial set a $50.00 target price on Corcept Therapeutics in a research note on Wednesday, December 31st. Canaccord Genuity Group upped their price target on Corcept Therapeutics from $99.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, January 23rd. Wolfe Research downgraded shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price target on the stock. in a report on Wednesday, December 31st. Finally, UBS Group initiated coverage on shares of Corcept Therapeutics in a research note on Tuesday, December 16th. They set a “neutral” rating and a $95.00 price objective for the company. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Corcept Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $83.50.

Insider Transactions at Corcept Therapeutics

In other news, insider Joseph Douglas Lyon sold 5,000 shares of Corcept Therapeutics stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $79.53, for a total value of $397,650.00. Following the transaction, the insider owned 10,277 shares in the company, valued at approximately $817,329.81. The trade was a 32.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Joseph K. Belanoff sold 40,000 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $79.77, for a total value of $3,190,800.00. Following the completion of the sale, the chief executive officer owned 2,701,370 shares of the company’s stock, valued at $215,488,284.90. The trade was a 1.46% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 129,500 shares of company stock worth $8,665,500. 20.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Royal Bank of Canada lifted its holdings in Corcept Therapeutics by 18.9% in the first quarter. Royal Bank of Canada now owns 15,385 shares of the biotechnology company’s stock worth $1,757,000 after buying an additional 2,444 shares during the period. Amundi purchased a new stake in shares of Corcept Therapeutics during the first quarter valued at approximately $450,000. NewEdge Advisors LLC bought a new stake in Corcept Therapeutics in the 1st quarter worth about $518,000. EverSource Wealth Advisors LLC grew its position in Corcept Therapeutics by 273.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,441 shares of the biotechnology company’s stock worth $106,000 after purchasing an additional 1,055 shares during the period. Finally, Marshall Wace LLP increased its position in Corcept Therapeutics by 795.3% during the second quarter. Marshall Wace LLP now owns 46,200 shares of the biotechnology company’s stock valued at $3,391,000 after acquiring an additional 41,040 shares during the last quarter. 93.61% of the stock is owned by hedge funds and other institutional investors.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.